2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in 2025? It's hard to say, but many individual biotech stocks still look like solid long-term picks.That includes CRISPR Therapeutics (NASDAQ: CRSP) and Exelixis (NASDAQ: EXEL). The former is well in the red for the year, while the latter has crushed the broader market this year. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. Read on to learn more.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool